Conferences
Stay informed about upcoming pharma conferences, symposiums, and events. Discover opportunities to connect with industry experts, thought leaders, and researchers. Stay updated about the latest scientific advancements, networking opportunities, and educational programs in the pharmaceutical field.
Medtronic, Edwardsâ TAVR devices match surgery in long-term studies
At the Transcatheter Cardiovascular Therapeutics conference in San Francisco, both Medtronic and Edwards Lifesciences unveiled the latest results from ongoing ...
Abbottâs Amulet, Bostonâs Watchman equal in heart occluder trial
The study, presented as a late-breaking feature at the Transcatheter Cardiovascular Therapeutics conference in San Francisco, assessed the safety and ...
Daiichi and AstraZeneca expand ADC pipelines after Enhertu triumph
At the European Society for Medical Oncology (ESMO) Congress, Daiichi Sankyo made a significant impact by striking a $4 billion ...
Moderna, BioNTech face hurdles in cancer vaccine production after COVID success
Moderna and BioNTech, both navigating their post-COVID future while reimagining cancer treatments, have encountered manufacturing hurdles along their respective journeys. ...
Keytruda: Merckâs breakthrough cancer drug with mixed results at ESMO
Merck & Co. made significant strides at this year’s European Society for Medical Oncology (ESMO) congress, presenting a series of ...
BioNTechâs CAR-T/CARVac Combo Shows High Response Rates in Solid Tumors, But Also Higher Toxicity (ESMO 2023)
ESMO 2023: LBA35 BioNTech’s innovative manufacturing process for CAR-T therapy, BNT211, has shown promising results in treating solid tumors. While ...
Dato-DXd Shows Efficacy in Lung Cancer, But Safety Issues Remain (ESMO 2023)
ESMO 2023: LBA12 During the Presidential Symposium at the ESMO Congress 2023 in Madrid, a study revealed that datopotamab deruxtecan, ...
Pluvicto Improves Survival in Earlier Prostate Cancer, But Faces Regulatory Hurdles (ESMO 2023)
ESMO 2023: LBA13 Novartis is eagerly advancing its radiotherapy drug, Pluvicto, with aspirations of its potential in earlier prostate cancer ...
Ambrxâs ARX517 Shows Promising Efficacy and Safety in Advanced Prostate Cancer (ESMO 2023)
ESMO 2023: 1804P As of the data cutoff date in September 2023, the results from the study show that increasing ...
Merusâ Zeno Shows Higher Response Rates in NRG1+ Pancreatic and Lung Cancers (ESMO 2023)
ESMO 2023: 1618P Currently, Ipsen’s Onivyde is the standard of care, but it offers only a 7% chance of response ...
Imfinzi and Lynparza Combo Improves Survival in Endometrial Cancer Trial (ESMO 2023)
ESMO 2023: LBA41 AstraZeneca is exploring a potentially powerful approach in the fight against endometrial cancer, suggesting that combining their ...
Cabometyx Shows Dramatic Benefits in Advanced Neuroendocrine Tumors (ESMO 2023)
ESMO 2023: LBA53 Exelixis made headlines last month when its Cabometyx exceeded expectations in the treatment of neuroendocrine tumors (NETs), ...
Padcev-Keytruda Combo Doubles Survival in First-Line Bladder Cancer Trial (ESMO 2023)
ESMO 2023: LBA6 Exciting results from the EV-302 phase 3 trial suggest that the partnership between Seagen and Astellas’ antibody-drug ...
Opdivo Beats Chemo in First-Line Bladder Cancer, But Keytruda-Padcev Combo Looms Large (ESMO 2023)
ESMO 2023: LBA7 Bladder cancer has presented a unique challenge for immunotherapies, with Bristol Myers Squibb’s Opdivo making strides, but ...
Lumakras-Vectibix combo outperforms standard therapy in KRAS G12C-mutated colorectal cancer (ESMO 2023)
ESMO 2023: LBA10 Nevertheless, a shadow has been cast over the KRAS inhibitor due to recent criticisms by FDA advisors. ...
Lilly Unveils Exciting Phase III Showdown: Retevmo vs. Keytruda & Chemotherapy in RET Fusion-Positive NSCLC
ESMO 2023: LBA4 RET fusion is found in about 1-2% of patients with non-small cell lung cancer. Retevmo, a highly ...
Phase III ALINA study shows Alecensaâs superior disease-free survival benefit in early-stage lung cancer patients
ESMO 2023: LBA2 About 4-5% of NSCLC cases are identified with ALK rearrangements. In 2015, Alecensa (alectinib) received accelerated approval ...
A novel combination therapy of garsorasib and cetuximab for KRAS G12C mutated colorectal cancer patients
Dâ1553 is a small-molecule inhibitor designed to selectively target KRAS G12C and is currently undergoing Phase II clinical trials. It ...
Combination of Osimertinib and Chemotherapy Enhances Brain Control in Advanced EGFR-Mutated Lung Cancer: Results from FLAURA2 Trial
ESMO: LBA68 EGFR mutations are found in 10%-15% of non-small cell lung cancer (NSCLC) cases among European and Caucasian populations. ...
Positive Interim Results from Global Phase III MATTERHORN Study: Imfinzi plus FLOT Demonstrates Clinically Meaningful Improvement in Key Secondary Endpoint (ESMO 2023)
ESMO 2023: LBA73 The results of a MATTERHORN trial was presented in ESMO 2023. The trial tested the effect of ...
Phase II DeLLphi-301 Study Reveals Impressive Antitumor Activity of Amgen’s First-in-Class Bispecific Antibody Tarlatamab (ESMO 2023)
ESMO 2023: LBA92 Most SCLC patients are diagnosed with cancer that has already spread beyond the lungs, and their average ...
Promising Outcomes and Safety Profile of Krazati Combined with Pembrolizumab in Treatment-NaĂŻve, Advanced NSCLC Patients with KRASG12C Mutation: Insights from the Phase II/III KRYSTAL-7 Study (ESMO 2023)
ESMO 2023: LBA65 NSCLC with KRAS mutations is a difficult market with few treatment options and many unmet needs. Krazati ...
KEYNOTE-671 Trial: Keytruda Sets New Standards in the Perioperative Treatment Landscape (ESMO 2023)
ESMO 2023: LBA56 Neoadjuvant NSCLC is a challenging market with few treatment options and many unmet needs. Merckâs Keytruda is ...
Keytruda’s Success in KEYNOTE-756 Trial Ushers in a New Era for Early-Stage High-Risk ER+/HER2â Breast Cancer Treatment (ESMO 2023)
ESMO 2023: LBA21 Keytruda (pembrolizumab) is a highly specific, human-made antibody that targets the PD-1 pathway and prevents cancer cells ...
Rybrevant Redefines First-Line Care for Patients with EGFR Exon 20 Insertion Mutation (ESMO 2023)
ESMO 2023: LBA5 Targeted therapies have revolutionized the treatment of EGFR-mutant NSCLC in the last 20 years. However, EGFR exon ...
ESMO 2023: Bristol Myers Squibbâs Opdivo Plus Chemotherapy Improves Survival in Resectable NSCLC: CheckMate -816 Trial
ESMO 2023: Abstract ID 1261O Treating early-stage NSCLC presents numerous obstacles, given the restricted therapeutic alternatives available. In this landscape, ...
How Keytruda Improved Survival Outcomes for Early-Stage TNBC Patients: KEYNOTE-522 Trial
ESMO 2023: LBA18 Underpinning this approval is the seminal KEYNOTE-522 trial, a Phase III study that diverges from pre-2021 tactics ...
ESMO 2023: GSKâs Jemperli beats Merckâs Keytruda in lung cancer survival trial
In a groundbreaking clinical trial, GSK has achieved remarkable patient survival results with its PD-1 inhibitor, Jemperli, when compared to ...
Tagrisso-chemo combo delays EGFR NSCLC progression by 9 months in first-line (IASLC WCLC 2023 Conference)
Against the formidable challenge of non-small cell lung cancer (NSCLC), AstraZeneca’s Tagrisso (osimertinib), when partnered with chemotherapy, has unveiled remarkable ...
Fasenra, a new treatment for EGPA, achieved remission in Phase III trial (IASLC WCLC 2023 Conference)
The MANDARA Phase III trial has shed new light on the effectiveness of AstraZeneca’s Fasenra (benralizumab). Unveiling favorable high-tier outcomes, ...
